These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2327436)

  • 1. Diagnosis and treatment of high-grade myeloma.
    Barlogie B
    Am J Med; 1990 Apr; 88(4):445-6. PubMed ID: 2327436
    [No Abstract]   [Full Text] [Related]  

  • 2. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
    Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
    J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents.
    Ronchetti AM; Isnard F; Buffet M; Coman T; Gorin NC; Coppo P; Garderet L; Malak S
    Leuk Lymphoma; 2013 May; 54(5):1117-9. PubMed ID: 23035656
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma.
    Novella E; Madeo D; Albiero E; Roberti S; Castaman G; Elice F; Rodeghiero F
    Leuk Lymphoma; 2004 Jul; 45(7):1497-9. PubMed ID: 15359659
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloma presenting during pregnancy.
    Smith D; Stevens J; Quinn J; Cavenagh J; Ingram W; Yong K
    Hematol Oncol; 2014 Mar; 32(1):52-5. PubMed ID: 23996410
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy of conventional chemotherapy in a primary double-refractory IgM multiple myeloma.].
    Innao V; Allegra A; Allegra AG; Musolino C
    Recenti Prog Med; 2019; 110(7):364-367. PubMed ID: 31379372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects.
    D'Sa S; Yong K; Kyriakou C; Bhattacharya S; Peggs KS; Foulkes B; Watts MJ; Ings SJ; Ardeshna KM; Goldstone AH; Williams CD
    Br J Haematol; 2004 Jun; 125(6):756-65. PubMed ID: 15180865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

  • 9. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
    Erikci AA; Ozturk A; Tekgunduz E; Sayan O
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):E14-5. PubMed ID: 19717372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPACE-based chemotherapy in the era of myeloma novel agents: A UK multicentre study.
    Djebbari F; De Abrew K; Salhan B; Panitsas F; Hossain MI; Eyre TA; Willan J; Ramasamy K; Basu S; Jenner M; Kothari J
    Eur J Haematol; 2020 Aug; 105(2):231-233. PubMed ID: 32268442
    [No Abstract]   [Full Text] [Related]  

  • 13. [Progress in the treatment of multiple myeloma].
    Wada M; Mizoguchi H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.
    Corso A; Arcaini L; Caberlon S; Zappasodi P; Mangiacavalli S; Lorenzi A; Rusconi C; Troletti D; Maiocchi MA; Pascutto C; Morra E; Lazzarino M
    Haematologica; 2002 Oct; 87(10):1041-5. PubMed ID: 12368158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemophagocytic lymphohistiocytosis after chemotherapy for multiple myeloma.
    Terrovitis JV; Matsouka C; Anagnostopoulos A; Anastasiou-Nana MI; Dimopoulos AM
    Clin Lymphoma; 2004 Dec; 5(3):194-6. PubMed ID: 15636696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infiltration of the spinal cord in a patient with multiple myeloma.
    Varettoni M; Corso A; Zappasodi P; Calliada F; Castagnola C; Mangiacavalli S; Lazzarino M
    J Clin Oncol; 2008 Sep; 26(25):4207-9. PubMed ID: 18757337
    [No Abstract]   [Full Text] [Related]  

  • 17. Addition of verapamil to overcome drug resistance in multiple myeloma: preliminary clinical observations in 10 patients.
    Trümper LH; Ho AD; Wulf G; Hunstein W
    J Clin Oncol; 1989 Oct; 7(10):1578-9. PubMed ID: 2778486
    [No Abstract]   [Full Text] [Related]  

  • 18. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
    Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.
    Park S; Lee SJ; Jung CW; Jang JH; Kim SJ; Kim WS; Kim K
    Ann Hematol; 2014 Jan; 93(1):99-105. PubMed ID: 24240976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.